Abstract
You have accessJournal of UrologyCME1 Apr 2023PD39-12 IMPACT OF PROSTATE-SPECIFIC ANTIGEN TESTING PATTERN ON CANCER MORTALITY AMONG BLACK AND WHITE MEN DIAGNOSED WITH PROSTATE CANCER: A LARGE, URBAN HEALTH SYSTEM COHORT ANALYSIS Matthew Davis, Alexander Stephens, Sohrab Arora, Eric Williams, Chase Morrison, Nicholas Corsi, Ivan Rakic, Rafe Affas, Akshay Sood, Craig Rogers, and Firas Abdollah Matthew DavisMatthew Davis More articles by this author , Alexander StephensAlexander Stephens More articles by this author , Sohrab AroraSohrab Arora More articles by this author , Eric WilliamsEric Williams More articles by this author , Chase MorrisonChase Morrison More articles by this author , Nicholas CorsiNicholas Corsi More articles by this author , Ivan RakicIvan Rakic More articles by this author , Rafe AffasRafe Affas More articles by this author , Akshay SoodAkshay Sood More articles by this author , Craig RogersCraig Rogers More articles by this author , and Firas AbdollahFiras Abdollah More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003342.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Randomized studies addressing the role of prostate-specific antigen (PSA) screening on mortality in Black men are lacking. The aim of our study was to examine the impact of PSA on survival based on screening patterns and compare it between Black and White Men in a racially diverse North American population. METHODS: This analysis included 6,378 Black and non-Hispanic White men with prostate cancer diagnosis who received care between the years 2000 and 2019, through our health system, and had at least one follow-up post diagnosis. For all patients, PSA testing data were examined categorically for the 5 years before diagnosis (going back to 1995) as follows: never, some (between 1-4 tests/5 years), and yearly testing (5 tests/5 years). The records were linked to Michigan Vital Records registry to certify survival status. Kaplan-Meier curves were used to estimate survival rate. Fine-Gray regression examined numerically the impact of PSA testing rate (from 0 to 5 years) on cancer-specific mortality (CSM), after accounting for available confounders. RESULTS: Median (IQR) for age and PSA at diagnosis were 67.2 (60.8 - 73.8) years, and 5.8 (4.4 - 9.6) ng/ml, respectively. Yearly PSA testing was more frequent in White (5.2%) versus Black (3.2%) men (p value<0.001). For the never, some and yearly testing categories, the 10-year cancer specific survival was respectively 87.7%, 94.2%, and 95.4% in Black men (p<0.0001), and 81.5%, 93.0%, 98.8% in White men (p<0.0001). On multivariable analysis, increased PSA testing rate prior to diagnosis was associated with more favorable CSM rates for Black men (HR: 0.14; 95% CI 0.08-0.23; p<0.001) as well as White men (HR: 0.31; 95% CI 0.19-0.49; p<0.001). CONCLUSIONS: In this retrospective cohort, more frequent PSA testing was associated with a reduced risk of CSM in both Black and non-Hispanic White men who were diagnosed with prostate cancer. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1050 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthew Davis More articles by this author Alexander Stephens More articles by this author Sohrab Arora More articles by this author Eric Williams More articles by this author Chase Morrison More articles by this author Nicholas Corsi More articles by this author Ivan Rakic More articles by this author Rafe Affas More articles by this author Akshay Sood More articles by this author Craig Rogers More articles by this author Firas Abdollah More articles by this author Expand All Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.